The Psychiatry Consortium is again seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions:
psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders
The Psychiatry Consortium intend to fund projects which:
- show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
- will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability
Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.
For help determining whether your project is in scope, visit the Psychiatry Consortium Website, or if you are interested in finding out more about the scope of the call and the funding model, you can watch the latest webinar.
Applications can be submitted via the Psychiatry Consortium website until the 12th June 2020, 23.59 (BST).
The Psychiatry Consortium, managed by Medicines Discovery Catapult, brings together academia, industry, charity and government-funded organisations to develop and deliver a portfolio of innovative collaborative projects to identify and validate new drug targets for psychiatric diseases.
